Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia.
Sales of atypical antipsychotics have expanded rapidly as their use for treatment of schizophrenia and other illnesses has increased. The CATIE trial was designed to evaluate the cost-effectiveness of these medications. Cost-effectiveness analysis in CATIE examined the benefits and costs of treatments and attempted to determine whether one treatment would result in better outcomes and lower costs than another one. While the data from CATIE on cost-effectiveness have not been analyzed yet, it is still possible to consider the potential implications of the analysis, including how the roles of researchers and stakeholders should be considered in deciding optimal clinical practices and public policies.
Rosenheck
Robert A
RA
Department of Psychiatry, Yale University School of Medicine and VA Northeast Program Evaluation Center, West Haven, Conn., USA.
Lieberman
Jeffrey A
JA
D014150:Antipsychotic Agents / Q000191:economics* / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003363:Cost Control; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006291:Health Policy; D006801:Humans; D011050:Policy Making; D012559:Schizophrenia / Q000188:drug therapy* / Q000191:economics*; D016896:Treatment Outcome
D014150:Antipsychotic Agents